NREP
NEW REPRESENTATIVE AT IB RECEIVED
09/20/2024
Back to search
Official data from USPTO
CELLFORCURE
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
CELLFORCURE
ST13
US500000079106607Class
5, 35, 36, 40, 42, 44, 45
Filing
79106607
Registration
4255776
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
57
Latest update
09/20/2024
Trademark type
Word
Nice classes
5, 35, 36, 40, 42, 44, 45
Filing date
10/12/2011
Registration date
12/11/2012
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/23/2023
Last transaction
06/23/2023
Responsible office
United States Patent and Trademark Office
Status code
709
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
FR
Examiner
SALEM-HOWEY, AISHA
Law office
M40
Holders and representatives
Holders
CELLFORCURE
L. B. (pessoa física)
LABORATOIRE FRANCAIS DU; FRACTIONNEMENT; ET DES BIOTECHNOLOGIES
Representatives
Maury M. Tepper, III Tepper & Eyster, PLLC
Technical classification
Nice Classes
Class 5Class 35Class 36Class 40Class 42Class 44Class 45
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical and veterinary preparations for the treatment of humans and animals suffering from diseases treated by cell therapy or regenerative medicine products ; sanitary preparations for medical purposes; medical plasters; material for dental fillings and dental impressions; all purpose disinfectants
Class 35
Retail store services featuring tissues and their by-products and preparations for cell therapy for autologous or allogenic therapy purposes; marketing services; importing and exporting agencies for health productsparticularly of medicines for human purposes including medicines for experimental purposesbiological products for experimental purposespreparations for cell therapy and medicines for innovative therapies
Class 36
Financial and real estate affairs in every type of financialreal estate or securities-related operation and in all commercial or industrial firms in the field of healthfinancial consultancyfinancial analysiscapital accumulation and investmentreal estate appraisal; real estate brokeragereal estate acquisition services for business assets; real estate brokeragerental of commercial property; real estate brokerageleasing and management for others of commercial property; rentalleasing and management of real estateparticularly of all commercial properties in the nature of facilitiesbusinessesfactories and workshops in the health sector
Class 40
Cryopreservationfor autologous or allogenic therapy purposesof human tissues and their by-products and preparations for cell therapy; custom manufacturing for othersmanufacturing of pharmaceutical and veterinary preparations for health carefor the treatment of humans and animals suffering from diseases treated by cell therapy or regenerative medicine productsparticularly medicines for human purposes including medicines for experimental purposesbiological products for experimental purposespreparations for cell therapy and medicines for innovative therapies
Class 42
Research and developmentfor autologous or allogenic therapy purposesfor tissues and their by-products and preparations for cell therapy; research and development of health preparationsparticularly of medicines for human purposes including medicines for experimental purposesbiological products for experimental purposespreparations for cell therapy and medicines for innovative therapies; scientific studies relating to the health sector in the field of cell therapy and regenerative medicine
Class 44
Advice and assistanceproviding information in the field of cell therapy and regenerative medicine for public laboratories and companiesparticularly those in the medical and health sectors
Class 45
Legal servicesadvice and assistance for public laboratories and companiesparticularly those in the medical and health sectorson state and federal regulatory compliance requirements; legal serviceslicensing of patented or non-patented goodsprocedures and inventions in the field of health
Publications
History of USPTO decisions and trademark events.
57 publications found
INNT
TOTAL INVALIDATION PROCESSED BY THE IB
04/01/2024
INTS
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
03/02/2024
INPC
INVALIDATION PROCESSED
03/02/2024
INTR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
02/23/2024
C71T
CANCELLED SECTION 71
06/23/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
07/26/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
07/26/2022
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
07/26/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
07/26/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
07/26/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
07/26/2022
REM4
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
12/11/2021
RNWL
INTERNATIONAL REGISTRATION RENEWED
11/05/2021
NREP
NEW REPRESENTATIVE AT IB RECEIVED
09/24/2021
INNP
PARTIAL INVALIDATION PROCESSED BY THE IB
06/12/2020
INPS
PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
05/07/2020
INPC
INVALIDATION PROCESSED
05/07/2020
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
02/13/2020
CHLD
CHANGE OF OWNER RECEIVED FROM IB
12/27/2019
NA75
NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
06/13/2019
C75P
REGISTERED - PARTIAL SEC. 71 ACCEPTED & SEC. 15 ACK.
06/13/2019
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
06/13/2019
ES75
TEAS SECTION 71 & 15 RECEIVED
06/10/2019
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
12/11/2017
NREP
NEW REPRESENTATIVE AT IB RECEIVED
03/27/2015
NREP
NEW REPRESENTATIVE AT IB RECEIVED
07/21/2014
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
04/16/2013
FICS
FINAL DISPOSITION NOTICE SENT TO IB
03/15/2013
FIMP
FINAL DISPOSITION PROCESSED
03/15/2013
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
03/11/2013
R.PR
REGISTERED-PRINCIPAL REGISTER
12/11/2012
GPNX
NOTIFICATION PROCESSED BY IB
10/16/2012
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/25/2012
PUBO
PUBLISHED FOR OPPOSITION
09/25/2012
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
09/05/2012
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
09/05/2012
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
09/05/2012
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
08/23/2012
ALIE
ASSIGNED TO LIE
08/22/2012
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/14/2012
XAEC
EXAMINER'S AMENDMENT ENTERED
08/14/2012
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
08/14/2012
GNEA
EXAMINERS AMENDMENT E-MAILED
08/14/2012
CNEA
EXAMINERS AMENDMENT -WRITTEN
08/14/2012
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/25/2012
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/25/2012
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/25/2012
RFNP
REFUSAL PROCESSED BY IB
03/06/2012
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
02/10/2012
RFRR
REFUSAL PROCESSED BY MPU
02/09/2012
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
02/08/2012
CNRT
NON-FINAL ACTION WRITTEN
02/07/2012
DOCK
ASSIGNED TO EXAMINER
01/31/2012
MAFR
APPLICATION FILING RECEIPT MAILED
01/03/2012
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
12/28/2011
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
12/22/2011
Continuous trademark protection
Get notified about every new filing that threatens CELLFORCURE or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.